3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Carcinoma, Hepatocellular
59
Cholangiocarcinoma
19
Carcinoma, Renal Cell
16
Biliary Tract Neoplasms
11
Stomach Neoplasms
9
Thyroid Neoplasms
8
Endometrial Neoplasms
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Neoplasms
7
Melanoma
6
Uterine Cervical Neoplasms
5
Thyroid Carcinoma, Anaplastic
5
Neuroendocrine Tumors
5
Carcinoma, Non-Small-Cell Lung
5
Recurrence
4
Ovarian Neoplasms
4
Liver Neoplasms
4
Thyroid Cancer, Papillary
3
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Neoplasm Metastasis
3
Cirrhosis, Familial, with Pulmonary Hypertension
3
Brain Neoplasms
3
Advanced Biliary Tract Cancer
3
Adenocarcinoma, Follicular
3
Vulvar Neoplasms
2
Uveal Melanoma
2
Triple Negative Breast Neoplasms
2
Thymoma
2
Solid Tumors
2
Interventions
Bevacizumab
234
Fluorouracil
220
Oxaliplatin
216
Irinotecan
215
Leucovorin
199
Capecitabine
153
Cetuximab
146
Panitumumab
70
Folfox protocol
51
regorafenib
43
Radiotherapy
38
pembrolizumab
37
IFL protocol
36
HMPL-013
36
trifluridine tipiracil drug combination
32
Nivolumab
32
Drug Therapy
26
Neoadjuvant Therapy
24
Trifluridine
18
Celecoxib
18
tislelizumab
17
XELOX
17
sintilimab
16
Trastuzumab
16
durvalumab
15
atezolizumab
15
aflibercept
15
Chemotherapy, Adjuvant
15
Biopsy
15
apatinib
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Colorectal Neoplasms
×
lenvatinib
×
Clear all
NCT03797326
2026-05-04
LEAP-005
Merck Sharp & Dohme LLC
Phase 2
Completed
611 enrolled
27 charts